IL5 and chronic obstructive pulmonary disease: In COPD, emerging therapies targeting eosinophil chemotactic and survival factors, including monoclonal antibodies directed at the IL5 ligand, IL5 receptor, IL4 receptor, and IL13 ligand, have been investigated [2].